Body Fat as Determinant of Female Gonadal Dysfunction

NCT ID: NCT03841981

Last Updated: 2025-08-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-01-31

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Reproduction requires from women enough energy depots to warrant an adequate nutritional supply to the fetus. Hence, adipose tissue is able to communicate with female hypothalamic-pituitary-ovary axis. The hypothesis of the project is that abnormalities in the quantity (absolute and relative to lean body mass), distribution and/or function of adipose tissue are associated with functional forms of female gonadal dysfunction in predisposed women, in a spectrum of anomalies that go from hypothalamic amenorrhea to the polycystic ovary syndrome (PCOS). To challenge this hypothesis, the investigators will study 5 groups of 10 women each: women with exercise-associated hypothalamic amenorrhea, women without ovulatory dysfunction that exercise equally, non-hyperandrogenic patients with PCOS, hyperandrogenic patients with PCOS, and healthy control women comparable to those with PCOS. The aims of the study will be:

Primary objective: To identify novel signalling factors originating from adipose tissue and muscle using targeted and nontargeted evaluation of the proteome and of gene expression of superficial subcutaneous fat, deep subcutaneous fat (which mimics visceral adipose tissue) and skeletal muscle.

Secondary objectives:

1. To study the serum adipokine profile - including those identified by the primary objective - and circulating gut hormones during fasting and after a glucose load in the 5 groups of women, and their associations with sexual hormones and body fat distribution.
2. To study body composition and body fat distribution in these women and their relationships with:

2.1, Sex steroid profiles.

2.2. Classic cardiovascular risk factors: carbohydrate metabolism, lipid profiles and blood pressure.

2.3 Markers of low-grade chronic inflammation.

2.4. Oxidative stress markers.

2.5. Cardiovascular autonomic function.

2.6. Surrogate markers of subclinical atherosclerosis.

2.7. Circulating concentrations of endocrine disruptors.

2.8. Oral and gut microbiome.

The results will provide a better understanding of the mechanisms linking body energy depots with the female reproductive axis and, hopefully, the identification of potential biomarkers for the diagnosis and treatment of the disorders studied here.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polycystic Ovary Syndrome Hypothalamic Amenorrhea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

I- Hypothalamic amenorrhea

10 women with exercise-associated hypothalamic amenorrhea

Anthropometric and physical examination

Intervention Type DIAGNOSTIC_TEST

* Weight and height.
* Waist-to-hip ratio.
* Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\].

Indirect calorimetry, accelerometer and seven-day dietary recall

Intervention Type DIAGNOSTIC_TEST

Energy availability assessment.

Biochemical, hormonal and metabolic phenotyping

Intervention Type DIAGNOSTIC_TEST

* Lipid profile.
* Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.
* Sex steroid profile.
* Hypothalamic-pituitary-adrenal axis study.
* Ferrokinetic study.
* Subclinical chronic inflammatory markers.

Sonographic studies

Intervention Type DIAGNOSTIC_TEST

* Polycystic ovarian morphology.
* Carotid intima-media thickness.
* Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness.

24-hour Ambulatory blood pressure monitoring

Intervention Type DIAGNOSTIC_TEST

A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).

Percutaneous biopsy

Intervention Type PROCEDURE

Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.

Cardiovascular autonomic function studies

Intervention Type DIAGNOSTIC_TEST

Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.

Oral smear and feces specimen

Intervention Type DIAGNOSTIC_TEST

Microbiome studies.

II- Hyperandrogenic polycystic ovary syndrome

5 lean women with hyperandrogenic polycystic ovary syndrome. 5 women with weight excess and hyperandrogenic polycystic ovary syndrome.

Anthropometric and physical examination

Intervention Type DIAGNOSTIC_TEST

* Weight and height.
* Waist-to-hip ratio.
* Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\].

Indirect calorimetry, accelerometer and seven-day dietary recall

Intervention Type DIAGNOSTIC_TEST

Energy availability assessment.

Biochemical, hormonal and metabolic phenotyping

Intervention Type DIAGNOSTIC_TEST

* Lipid profile.
* Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.
* Sex steroid profile.
* Hypothalamic-pituitary-adrenal axis study.
* Ferrokinetic study.
* Subclinical chronic inflammatory markers.

Sonographic studies

Intervention Type DIAGNOSTIC_TEST

* Polycystic ovarian morphology.
* Carotid intima-media thickness.
* Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness.

24-hour Ambulatory blood pressure monitoring

Intervention Type DIAGNOSTIC_TEST

A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).

Percutaneous biopsy

Intervention Type PROCEDURE

Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.

Cardiovascular autonomic function studies

Intervention Type DIAGNOSTIC_TEST

Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.

Oral smear and feces specimen

Intervention Type DIAGNOSTIC_TEST

Microbiome studies.

III- Non-hyperandrogenic polycystic ovary syndrome

5 lean women with non-hyperandrogenic polycystic ovary syndrome 5 women with weight excess and non-hyperandrogenic polycystic ovary syndrome

Anthropometric and physical examination

Intervention Type DIAGNOSTIC_TEST

* Weight and height.
* Waist-to-hip ratio.
* Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\].

Indirect calorimetry, accelerometer and seven-day dietary recall

Intervention Type DIAGNOSTIC_TEST

Energy availability assessment.

Biochemical, hormonal and metabolic phenotyping

Intervention Type DIAGNOSTIC_TEST

* Lipid profile.
* Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.
* Sex steroid profile.
* Hypothalamic-pituitary-adrenal axis study.
* Ferrokinetic study.
* Subclinical chronic inflammatory markers.

Sonographic studies

Intervention Type DIAGNOSTIC_TEST

* Polycystic ovarian morphology.
* Carotid intima-media thickness.
* Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness.

24-hour Ambulatory blood pressure monitoring

Intervention Type DIAGNOSTIC_TEST

A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).

Percutaneous biopsy

Intervention Type PROCEDURE

Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.

Cardiovascular autonomic function studies

Intervention Type DIAGNOSTIC_TEST

Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.

Oral smear and feces specimen

Intervention Type DIAGNOSTIC_TEST

Microbiome studies.

IV- Trained women without ovulatory dysfunction

10 women who exercise as intensively as women with exercise-associated hypothalamic amenorrhea but with normal ovulatory cycles.

Anthropometric and physical examination

Intervention Type DIAGNOSTIC_TEST

* Weight and height.
* Waist-to-hip ratio.
* Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\].

Indirect calorimetry, accelerometer and seven-day dietary recall

Intervention Type DIAGNOSTIC_TEST

Energy availability assessment.

Biochemical, hormonal and metabolic phenotyping

Intervention Type DIAGNOSTIC_TEST

* Lipid profile.
* Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.
* Sex steroid profile.
* Hypothalamic-pituitary-adrenal axis study.
* Ferrokinetic study.
* Subclinical chronic inflammatory markers.

Sonographic studies

Intervention Type DIAGNOSTIC_TEST

* Polycystic ovarian morphology.
* Carotid intima-media thickness.
* Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness.

24-hour Ambulatory blood pressure monitoring

Intervention Type DIAGNOSTIC_TEST

A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).

Percutaneous biopsy

Intervention Type PROCEDURE

Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.

Cardiovascular autonomic function studies

Intervention Type DIAGNOSTIC_TEST

Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.

Oral smear and feces specimen

Intervention Type DIAGNOSTIC_TEST

Microbiome studies.

V- Non-hyperandrogenic healthy women

10 women matched by age and body mass index with women with polycystic ovary syndrome who do not perform physical activity on a regular basis

Anthropometric and physical examination

Intervention Type DIAGNOSTIC_TEST

* Weight and height.
* Waist-to-hip ratio.
* Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\].

Indirect calorimetry, accelerometer and seven-day dietary recall

Intervention Type DIAGNOSTIC_TEST

Energy availability assessment.

Biochemical, hormonal and metabolic phenotyping

Intervention Type DIAGNOSTIC_TEST

* Lipid profile.
* Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.
* Sex steroid profile.
* Hypothalamic-pituitary-adrenal axis study.
* Ferrokinetic study.
* Subclinical chronic inflammatory markers.

Sonographic studies

Intervention Type DIAGNOSTIC_TEST

* Polycystic ovarian morphology.
* Carotid intima-media thickness.
* Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness.

24-hour Ambulatory blood pressure monitoring

Intervention Type DIAGNOSTIC_TEST

A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).

Percutaneous biopsy

Intervention Type PROCEDURE

Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.

Cardiovascular autonomic function studies

Intervention Type DIAGNOSTIC_TEST

Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.

Oral smear and feces specimen

Intervention Type DIAGNOSTIC_TEST

Microbiome studies.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anthropometric and physical examination

* Weight and height.
* Waist-to-hip ratio.
* Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\].

Intervention Type DIAGNOSTIC_TEST

Indirect calorimetry, accelerometer and seven-day dietary recall

Energy availability assessment.

Intervention Type DIAGNOSTIC_TEST

Biochemical, hormonal and metabolic phenotyping

* Lipid profile.
* Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers.
* Sex steroid profile.
* Hypothalamic-pituitary-adrenal axis study.
* Ferrokinetic study.
* Subclinical chronic inflammatory markers.

Intervention Type DIAGNOSTIC_TEST

Sonographic studies

* Polycystic ovarian morphology.
* Carotid intima-media thickness.
* Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness.

Intervention Type DIAGNOSTIC_TEST

24-hour Ambulatory blood pressure monitoring

A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).

Intervention Type DIAGNOSTIC_TEST

Percutaneous biopsy

Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.

Intervention Type PROCEDURE

Cardiovascular autonomic function studies

Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.

Intervention Type DIAGNOSTIC_TEST

Oral smear and feces specimen

Microbiome studies.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Group I

* Body mass index between 18.5 and 25.0 kg/m2.
* Group 1 ovulatory dysfunction \[World Health Organization (WHO) classification\].
* Normal/low gonadotrophin levels \[follicle-stimulating hormone (FSH) and luteinizing (LH) \< 10 IU/l\] and low estradiol (\< 50 pg/ml).
* Moderate-vigorous intensity physical activity (\> 5 hours per week) plus low energy availability (\< 30 kcal/per kg of lean mass).
* Exclusion of secondary etiologies
* Informed consent signed.

Group II:

* Polycystic ovary syndrome phenotype I, II and III \[National Institute of Health (NIH)-2012\] with hyperandrogenemia (http://prevention.nih.gov/workshops/2012/resources.aspx).
* Body mass index between 18.5 and 40.0 kg/m2.
* Informed consent signed.

Group III:

* Polycystic ovary syndrome phenotype IV (NIH-2012) (http://prevention.nih.gov/workshops/2012/resources.aspx).
* Body mass index between 18.5 and 40.0 kg/m2.
* Informed consent signed.

Group IV:

* Body mass index between 18.5 and 25.0 kg/m2.
* Regular menses.
* Normal gonadotropins and estradiol levels at follicular phase.
* Moderate-vigorous intensity physical activity (\> 5 hours per week) with normal energy availability (\> 30 kcal/per kg of lean mass).
* Informed consent signed.

Group V:

* No signs or symptoms of hyperandrogenism.
* No exercise or mild intensity physical activity.
* Regular menses.
* Body mass index between 18.5 and 40.0 kg/m2.
* Informed consent signed.

Exclusion Criteria

* Oral drugs interfering with ovulation (glucocorticoids, antipsychotics, antidepressants, contraceptives, sex steroids and/or opioids) for the previous 6 months to study inclusion.
* Current pregnancy or lactation, or during the previous 6 months to study inclusion.
* Asherman's syndrome or outflow tract disorders.
* Current smoking or alcohol intake \> 40 g per day.
* Previous diagnosis of glucose intolerance, hypertension, dyslipidemia, known heart or lung diseases, kidney disease, liver disease, celiac disease or any other malabsorptive condition, chronic inflammatory disease or malignancy.
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Instituto de Salud Carlos III

OTHER_GOV

Sponsor Role collaborator

University of Alcala

OTHER

Sponsor Role collaborator

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Héctor F Escobar-Morreale, PhD, MD

Role: PRINCIPAL_INVESTIGATOR

Diabetes, Obesity and Human Reproduction Research Group (CIBERDEM), Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain

Manuel Luque-Ramírez, PhD, MD

Role: PRINCIPAL_INVESTIGATOR

Diabetes, Obesity and Human Reproduction Research Group (CIBERDEM), Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Universidad de Alcalá, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Endocrinology and Nutrition

Madrid, Madrid, Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alejandra Quintero Tobar

Role: CONTACT

34913369029

Sara de Lope Quiñones

Role: CONTACT

34913369029

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Alejandra Quintero Tobar

Role: primary

34913369029

Sara de Lope Quiñones

Role: backup

34913369029

References

Explore related publications, articles, or registry entries linked to this study.

Ortiz-Flores AE, Luque-Ramirez M, Fernandez-Duran E, Alvarez-Blasco F, Escobar-Morreale HF. Diagnosis of disorders of glucose tolerance in women with polycystic ovary syndrome (PCOS) at a tertiary care center: fasting plasma glucose or oral glucose tolerance test? Metabolism. 2019 Apr;93:86-92. doi: 10.1016/j.metabol.2019.01.015. Epub 2019 Jan 30.

Reference Type BACKGROUND
PMID: 30710572 (View on PubMed)

Luque-Ramirez M, Jimenez-Mendiguchia L, Garcia-Cano A, Fernandez-Duran E, de Dios Rosa V, Nattero-Chavez L, Ortiz-Flores AE, Escobar-Morreale HF. Certified testosterone immunoassays for hyperandrogenaemia. Eur J Clin Invest. 2018 Dec;48(12):e13029. doi: 10.1111/eci.13029. Epub 2018 Oct 8.

Reference Type BACKGROUND
PMID: 30229887 (View on PubMed)

Insenser M, Murri M, Del Campo R, Martinez-Garcia MA, Fernandez-Duran E, Escobar-Morreale HF. Gut Microbiota and the Polycystic Ovary Syndrome: Influence of Sex, Sex Hormones, and Obesity. J Clin Endocrinol Metab. 2018 Jul 1;103(7):2552-2562. doi: 10.1210/jc.2017-02799.

Reference Type BACKGROUND
PMID: 29897462 (View on PubMed)

Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018 May;14(5):270-284. doi: 10.1038/nrendo.2018.24. Epub 2018 Mar 23.

Reference Type BACKGROUND
PMID: 29569621 (View on PubMed)

Escobar-Morreale HF. The Role of Androgen Excess in Metabolic Dysfunction in Women : Androgen Excess and Female Metabolic Dysfunction. Adv Exp Med Biol. 2017;1043:597-608. doi: 10.1007/978-3-319-70178-3_26.

Reference Type BACKGROUND
PMID: 29224112 (View on PubMed)

Montes-Nieto R, Insenser M, Murri M, Fernandez-Duran E, Ojeda-Ojeda M, Martinez-Garcia MA, Luque-Ramirez M, Escobar-Morreale HF. Plasma thiobarbituric acid reactive substances (TBARS) in young adults: Obesity increases fasting levels only in men whereas glucose ingestion, and not protein or lipid intake, increases postprandial concentrations regardless of sex and obesity. Mol Nutr Food Res. 2017 Nov;61(11). doi: 10.1002/mnfr.201700425. Epub 2017 Aug 29.

Reference Type BACKGROUND
PMID: 28722287 (View on PubMed)

Escobar-Morreale HF, Martinez-Garcia MA, Montes-Nieto R, Fernandez-Duran E, Temprano-Carazo S, Luque-Ramirez M. Effects of glucose ingestion on circulating inflammatory mediators: Influence of sex and weight excess. Clin Nutr. 2017 Apr;36(2):522-529. doi: 10.1016/j.clnu.2016.01.015. Epub 2016 Jan 29.

Reference Type BACKGROUND
PMID: 26874912 (View on PubMed)

Insenser M, Montes-Nieto R, Martinez-Garcia MA, Escobar-Morreale HF. A nontargeted study of muscle proteome in severely obese women with androgen excess compared with severely obese men and nonhyperandrogenic women. Eur J Endocrinol. 2016 Mar;174(3):389-98. doi: 10.1530/EJE-15-0912. Epub 2015 Dec 15.

Reference Type BACKGROUND
PMID: 26671973 (View on PubMed)

Borruel S, Molto JF, Alpanes M, Fernandez-Duran E, Alvarez-Blasco F, Luque-Ramirez M, Escobar-Morreale HF. Surrogate markers of visceral adiposity in young adults: waist circumference and body mass index are more accurate than waist hip ratio, model of adipose distribution and visceral adiposity index. PLoS One. 2014 Dec 5;9(12):e114112. doi: 10.1371/journal.pone.0114112. eCollection 2014.

Reference Type BACKGROUND
PMID: 25479351 (View on PubMed)

Luque-Ramirez M, Escobar-Morreale HF. Polycystic ovary syndrome as a paradigm for prehypertension, prediabetes, and preobesity. Curr Hypertens Rep. 2014 Dec;16(12):500. doi: 10.1007/s11906-014-0500-6.

Reference Type BACKGROUND
PMID: 25304109 (View on PubMed)

Escobar-Morreale HF, Alvarez-Blasco F, Botella-Carretero JI, Luque-Ramirez M. The striking similarities in the metabolic associations of female androgen excess and male androgen deficiency. Hum Reprod. 2014 Oct 10;29(10):2083-91. doi: 10.1093/humrep/deu198. Epub 2014 Aug 7.

Reference Type BACKGROUND
PMID: 25104855 (View on PubMed)

Murri M, Insenser M, Luque M, Tinahones FJ, Escobar-Morreale HF. Proteomic analysis of adipose tissue: informing diabetes research. Expert Rev Proteomics. 2014 Aug;11(4):491-502. doi: 10.1586/14789450.2014.903158. Epub 2014 Mar 31.

Reference Type BACKGROUND
PMID: 24684164 (View on PubMed)

Murri M, Insenser M, Escobar-Morreale HF. Metabolomics in polycystic ovary syndrome. Clin Chim Acta. 2014 Feb 15;429:181-8. doi: 10.1016/j.cca.2013.12.018. Epub 2013 Dec 22.

Reference Type BACKGROUND
PMID: 24368231 (View on PubMed)

Luque-Ramirez M, Marti D, Fernandez-Duran E, Alpanes M, Alvarez-Blasco F, Escobar-Morreale HF. Office blood pressure, ambulatory blood pressure monitoring, and echocardiographic abnormalities in women with polycystic ovary syndrome: role of obesity and androgen excess. Hypertension. 2014 Mar;63(3):624-9. doi: 10.1161/HYPERTENSIONAHA.113.02468. Epub 2013 Dec 9.

Reference Type BACKGROUND
PMID: 24324038 (View on PubMed)

Escobar-Morreale HF. Reproductive endocrinology: Menstrual dysfunction--a proxy for insulin resistance in PCOS? Nat Rev Endocrinol. 2014 Jan;10(1):10-1. doi: 10.1038/nrendo.2013.232. Epub 2013 Nov 26. No abstract available.

Reference Type BACKGROUND
PMID: 24275746 (View on PubMed)

Insenser M, Escobar-Morreale HF. Proteomics and polycystic ovary syndrome. Expert Rev Proteomics. 2013 Oct;10(5):435-47. doi: 10.1586/14789450.2013.837665. Epub 2013 Oct 3.

Reference Type BACKGROUND
PMID: 24087928 (View on PubMed)

Murri M, Insenser M, Bernal-Lopez MR, Perez-Martinez P, Escobar-Morreale HF, Tinahones FJ. Proteomic analysis of visceral adipose tissue in pre-obese patients with type 2 diabetes. Mol Cell Endocrinol. 2013 Aug 25;376(1-2):99-106. doi: 10.1016/j.mce.2013.06.010. Epub 2013 Jun 18.

Reference Type BACKGROUND
PMID: 23791845 (View on PubMed)

Luque-Ramirez M, Martinez-Garcia MA, Montes-Nieto R, Fernandez-Duran E, Insenser M, Alpanes M, Escobar-Morreale HF. Sexual dimorphism in adipose tissue function as evidenced by circulating adipokine concentrations in the fasting state and after an oral glucose challenge. Hum Reprod. 2013 Jul;28(7):1908-18. doi: 10.1093/humrep/det097. Epub 2013 Apr 4.

Reference Type BACKGROUND
PMID: 23559188 (View on PubMed)

Insenser M, Montes-Nieto R, Murri M, Escobar-Morreale HF. Proteomic and metabolomic approaches to the study of polycystic ovary syndrome. Mol Cell Endocrinol. 2013 May 6;370(1-2):65-77. doi: 10.1016/j.mce.2013.02.009. Epub 2013 Feb 17.

Reference Type BACKGROUND
PMID: 23422073 (View on PubMed)

Borruel S, Fernandez-Duran E, Alpanes M, Marti D, Alvarez-Blasco F, Luque-Ramirez M, Escobar-Morreale HF. Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab. 2013 Mar;98(3):1254-63. doi: 10.1210/jc.2012-3698. Epub 2013 Feb 5.

Reference Type BACKGROUND
PMID: 23386652 (View on PubMed)

Montes-Nieto R, Insenser M, Martinez-Garcia MA, Escobar-Morreale HF. A nontargeted proteomic study of the influence of androgen excess on human visceral and subcutaneous adipose tissue proteomes. J Clin Endocrinol Metab. 2013 Mar;98(3):E576-85. doi: 10.1210/jc.2012-3438. Epub 2013 Jan 24.

Reference Type BACKGROUND
PMID: 23348399 (View on PubMed)

Alvarez-Blasco F, Luque-Ramirez M, Escobar-Morreale HF. Diet composition and physical activity in overweight and obese premenopausal women with or without polycystic ovary syndrome. Gynecol Endocrinol. 2011 Dec;27(12):978-81. doi: 10.3109/09513590.2011.579658. Epub 2011 May 24.

Reference Type BACKGROUND
PMID: 21609197 (View on PubMed)

Insenser M, Escobar-Morreale HF. Application of proteomics to the study of polycystic ovary syndrome. J Endocrinol Invest. 2011 Dec;34(11):869-75. doi: 10.3275/8108. Epub 2011 Nov 21.

Reference Type BACKGROUND
PMID: 22104628 (View on PubMed)

Escobar-Morreale HF, Samino S, Insenser M, Vinaixa M, Luque-Ramirez M, Lasuncion MA, Correig X. Metabolic heterogeneity in polycystic ovary syndrome is determined by obesity: plasma metabolomic approach using GC-MS. Clin Chem. 2012 Jun;58(6):999-1009. doi: 10.1373/clinchem.2011.176396. Epub 2012 Mar 16.

Reference Type BACKGROUND
PMID: 22427353 (View on PubMed)

Insenser M, Montes-Nieto R, Vilarrasa N, Lecube A, Simo R, Vendrell J, Escobar-Morreale HF. A nontargeted proteomic approach to the study of visceral and subcutaneous adipose tissue in human obesity. Mol Cell Endocrinol. 2012 Nov 5;363(1-2):10-9. doi: 10.1016/j.mce.2012.07.001. Epub 2012 Jul 14.

Reference Type BACKGROUND
PMID: 22796336 (View on PubMed)

Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis. Hum Reprod Update. 2013 May-Jun;19(3):268-88. doi: 10.1093/humupd/dms059. Epub 2013 Jan 9.

Reference Type BACKGROUND
PMID: 23303572 (View on PubMed)

Martinez-Garcia MA, Montes-Nieto R, Fernandez-Duran E, Insenser M, Luque-Ramirez M, Escobar-Morreale HF. Evidence for masculinization of adipokine gene expression in visceral and subcutaneous adipose tissue of obese women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab. 2013 Feb;98(2):E388-96. doi: 10.1210/jc.2012-3414. Epub 2013 Jan 21.

Reference Type BACKGROUND
PMID: 23337724 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PI18/01122

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dietary Reversal of the Reprometabolic Syndrome
NCT07227766 ACTIVE_NOT_RECRUITING NA